

European Prevention of Alzheimer's Dementia Consortium (EPAD)

[https://www.neurodegenerationresearch.eu/survey/european-prevention-of-alzheimer%^c2%⁹2s-dementia-consortium/](https://www.neurodegenerationresearch.eu/survey/european-prevention-of-alzheimer%c2%92s-dementia-consortium/)

Question

Principal Investigators

Related

Institution

Contact information of lead PI

Country

European Commission

Title of project or programme

European Prevention of Alzheimer's Dementia Consortium (EPAD)

Source of funding information

European Commission FP7-IMI-Seventh Framework Programme/Innovative Medicines Initiative

Total sum awarded (Euro)

€ 25,880,000

Start date of award

21/01/2015

Total duration of award in years

4.9

The project/programme is most relevant to:

Alzheimer's disease & other dementias

Keywords

Research Abstract

There is an urgent need for new treatments for Alzheimer's disease. The number of people affected worldwide is expected to reach over 100 million by 2050, yet despite intensive efforts over many years, there is still no cure for Alzheimer's and little in the way of treatments. Today, research increasingly focuses on ways to prevent the onset of Alzheimer's in the first place. The EPAD project is pioneering a novel, more flexible approach to clinical trials of drugs designed to prevent Alzheimer's dementia. Using an 'adaptive' trial design should deliver better results faster and at lower cost.

Lay Summary

Further information available at:

<http://ep-ad.org/>

Types:

Investments > €500k

Member States:

European Commission

Diseases:

Alzheimer's disease & other dementias

Years:

2016

Database Categories:

N/A

Database Tags:

N/A